CXCR3 and breast carcinoma: To confirm that miR-155–overexpressing breast cancer cells attract more activated T cells, we performed an in vitro T cell migration assay using OVA peptide 257–264 to stimulate OT-I CD8+ T cells, which express high levels of CXCR3 (23).